Eptifibatide is a small cyclic peptide that stops blood platelets from clumping together. Its design traces back to a protein in rattlesnake venom. This guide covers its structure, mechanism, FDA-labeled uses, landmark trials and label warnings, with sources checked on November 17, 2026.
Quick answer: Eptifibatide is a prescription glycoprotein IIb/IIIa inhibitor. Its label covers acute coronary syndrome and percutaneous coronary intervention (PCI), to lower the rate of death or new heart attack. It reversibly blocks the platelet receptor that binds fibrinogen. Bleeding and hypotension are its most common adverse reactions.
Vitrapep does not sell eptifibatide; this page is a reference summary of published research and regulatory information.
What is eptifibatide?
Eptifibatide is a glycoprotein IIb/IIIa inhibitor peptide. The label states: “Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue.” A disulfide bridge links the cysteine amide and the mercaptopropionyl unit, closing the ring (Baxter eptifibatide label, 2024).
It counts as a peptide because its ring is built from amino acids. ChEBI, quoted in PubChem, calls it a “synthetic homodetic cyclic peptide.” PubChem lists the formula as C35H49N11O9S2 and the molecular weight as 832.0 g/mol (PubChem CID 448812). See our guide to types of peptides for how cyclic peptides are grouped.
Its origin is unusual. In 1991, researchers described barbourin, a peptide from the venom of the southeastern pygmy rattlesnake. Barbourin was specific for the platelet receptor GPIIb-IIIa and carried a Lys-Gly-Asp (KGD) sequence (Scarborough et al., 1991). A 1997 review states that eptifibatide’s “active pharmacophore” is “derived from the structure of barbourin” (Phillips and Scarborough, 1997).
Drugs@FDA lists the original approval of Integrilin (NDA 020718) on May 18, 1998 (Drugs@FDA).
Eptifibatide: key facts
| Fact | Detail |
|---|---|
| Structure type | Cyclic heptapeptide (6 amino acids plus 1 mercaptopropionyl residue), closed by a disulfide bridge |
| Class | Glycoprotein IIb/IIIa inhibitor (antiplatelet) |
| Molecular formula | C35H49N11O9S2 |
| Molecular weight | 832.0 g/mol |
| First FDA approval | May 18, 1998 (Integrilin, NDA 020718) |
| Brand names (US) | Integrilin (listed as discontinued); generic eptifibatide labels |
How does eptifibatide work?
Platelets clump together when a surface receptor, glycoprotein IIb/IIIa, grabs bridging proteins such as fibrinogen. A 1997 review calls eptifibatide “a specific and robust inhibitor of the GP IIb-IIIa receptor function.”
The label states that eptifibatide “reversibly inhibits platelet aggregation” by blocking this receptor. It prevents “the binding of fibrinogen, von Willebrand factor” and other adhesive ligands to GP IIb/IIIa. The NCI Thesaurus, quoted in PubChem, adds that it “selectively and reversibly binds to and blocks” the receptor. The same review describes “the rapid reversibility of action of eptifibatide.”
What is eptifibatide approved for?
The eptifibatide label lists two indications:
- Acute coronary syndrome (ACS): to “decrease the rate of a combined endpoint of death or new myocardial infarction (MI)” in patients with ACS.
- Percutaneous coronary intervention (PCI): to decrease the rate of a combined end point of death, new MI or need for urgent intervention in patients undergoing PCI.
What did the key trials show?
PURSUIT. This double-blind, randomized, placebo-controlled trial enrolled 10,948 patients with acute coronary syndromes without persistent ST-segment elevation. Eptifibatide or placebo was added to standard therapy. The primary end point was death or nonfatal heart attack up to 30 days. It occurred in 14.2% with eptifibatide and 15.7% with placebo, an absolute drop of 1.5 percentage points (P = 0.04). Bleeding was more common with eptifibatide, with no increase in hemorrhagic stroke (PURSUIT Trial Investigators, 1998).
ESPRIT. This randomized, placebo-controlled trial enrolled 2,064 patients having PCI with a planned stent. It was stopped early for efficacy. Its primary end point combined death, heart attack, urgent target vessel revascularization and thrombotic bailout therapy at 48 hours. Rates were 6.6% with eptifibatide and 10.5% with placebo (P = 0.0015). Major bleeding was 1.3% versus 0.4% (P = 0.027) (ESPRIT Investigators, 2000). Both trials were in humans.
What side effects does the label list?
The eptifibatide label has no boxed warning. Its highlights state: “Bleeding and hypotension are the most commonly reported adverse reactions.” Its warnings and precautions cover bleeding and thrombocytopenia, a drop in platelet count.
The contraindications reflect the bleeding risk. They include a history of bleeding diathesis or active abnormal bleeding within the previous 30 days, severe hypertension, recent major surgery, and stroke. They also include use of another glycoprotein IIb/IIIa inhibitor, dependency on kidney dialysis, and hypersensitivity.
What is eptifibatide’s regulatory status, and how is it used in research?
Eptifibatide is a prescription drug. Drugs@FDA lists both Integrilin products under NDA 020718 as discontinued. A DailyMed search returns 12 generic eptifibatide labels, from makers including Baxter, Mylan, Meitheal and Sagent (DailyMed).
The research story behind eptifibatide began with venom screening in the lab. Barbourin was the only one of 62 snake venoms tested that was specific for GPIIb-IIIa over other integrins. That work fed the drug’s design, as the 1997 review describes.
Frequently asked questions about eptifibatide
Is eptifibatide a peptide?
Yes. It is a cyclic heptapeptide: six amino acids plus a mercaptopropionyl residue, closed by a disulfide bridge.
Does eptifibatide come from snake venom?
It is synthetic, but its design came from barbourin, a peptide in southeastern pygmy rattlesnake venom.
When was eptifibatide approved?
FDA approved Integrilin on May 18, 1998.
Is Integrilin still available?
Drugs@FDA lists Integrilin as discontinued. DailyMed lists 12 generic eptifibatide labels.
What are the main side effects?
Bleeding and hypotension, per the label. In ESPRIT, major bleeding was 1.3% with eptifibatide versus 0.4% with placebo.
What to know now
- Structure: cyclic heptapeptide; C35H49N11O9S2; 832.0 g/mol.
- Origin: designed from barbourin, a rattlesnake venom peptide with a KGD sequence.
- Mechanism: reversibly blocks platelet GP IIb/IIIa, stopping fibrinogen binding.
- Approval: Integrilin, May 18, 1998; brand now discontinued, generics on DailyMed.
- Evidence: PURSUIT 14.2% vs 15.7% (P = 0.04); ESPRIT 6.6% vs 10.5% (P = 0.0015).
- Safety: no boxed warning; bleeding and hypotension most common.
What we’re watching
Label updates across the 12 generic eptifibatide labels on DailyMed; Baxter’s was revised in May 2024. Related guides: bivalirudin and linaclotide, another disulfide-linked peptide.